United Therapeutics (NASDAQ:UTHR) Price Target Raised to $643.00

United Therapeutics (NASDAQ:UTHR) had its price objective increased by Royal Bank Of Canada from $587.00 to $643.00 in a research report released on Thursday,Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock.

A number of other research firms have also commented on UTHR. TD Cowen raised their price target on United Therapeutics from $525.00 to $575.00 and gave the stock a “buy” rating in a report on Wednesday. HC Wainwright raised their target price on United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Wells Fargo & Company lifted their target price on United Therapeutics from $423.00 to $466.00 and gave the company an “equal weight” rating in a report on Thursday. Morgan Stanley set a $447.00 price target on United Therapeutics in a research report on Wednesday, October 29th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. Nine analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $533.55.

United Therapeutics Stock Up 0.1%

Shares of NASDAQ:UTHR opened at $503.90 on Thursday. The firm has a market capitalization of $22.09 billion, a PE ratio of 18.06, a P/E/G ratio of 1.79 and a beta of 0.85. The company has a 50-day moving average price of $484.38 and a two-hundred day moving average price of $446.93. United Therapeutics has a twelve month low of $266.98 and a twelve month high of $537.19.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The company had revenue of $790.20 million for the quarter, compared to analysts’ expectations of $814.80 million. During the same period in the prior year, the company posted $6.19 EPS. United Therapeutics’s revenue was up 7.4% compared to the same quarter last year. Analysts anticipate that United Therapeutics will post 24.48 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO James Edgemond sold 21,000 shares of the stock in a transaction on Monday, December 1st. The shares were sold at an average price of $479.99, for a total value of $10,079,790.00. Following the transaction, the chief financial officer owned 8,142 shares of the company’s stock, valued at $3,908,078.58. This represents a 72.06% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $479.91, for a total transaction of $10,797,975.00. The SEC filing for this sale provides additional information. Insiders have sold 407,954 shares of company stock valued at $197,601,528 in the last three months. 10.30% of the stock is owned by insiders.

Institutional Investors Weigh In On United Therapeutics

A number of large investors have recently added to or reduced their stakes in UTHR. Torren Management LLC bought a new stake in United Therapeutics in the 4th quarter worth approximately $26,000. Activest Wealth Management raised its stake in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 56 shares in the last quarter. WealthCollab LLC lifted its holdings in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares during the last quarter. Rakuten Securities Inc. boosted its stake in shares of United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares in the last quarter. Finally, Entrust Financial LLC bought a new position in shares of United Therapeutics during the 4th quarter valued at $31,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Key United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Q4 outperformance and growth target — UTHR beat EPS expectations (reported strength in Tyvaso DPI sales) and management is targeting roughly a $4B revenue run‑rate by 2027 as several late‑stage product launches approach; this underpins the recent rally and longer‑term growth thesis. Read More.
• Positive Sentiment: Analysts lifting targets — Multiple firms raised price targets (examples: H.C. Wainwright, RBC, Oppenheimer), which supports further upside and institutional interest. Read More.
• Positive Sentiment: Bullish options flow — Unusually large call buying around the print suggests traders are positioning for further upside or volatility in the short term. Read More.
• Neutral Sentiment: Technical/relative strength recognition — UTHR earned a high RS rating (91), signaling market leadership but not guaranteeing direction near term. Read More.
• Neutral Sentiment: Mixed analyst views remain — while many bumped targets, some firms kept Hold/equal‑weight ratings, leaving near‑term consensus mixed. Read More.
• Negative Sentiment: Revenue missed consensus — Q4 revenue came in below Street estimates, which sparked an earlier pullback and is a reminder top‑line execution matters for the multiple. Read More.
• Negative Sentiment: Insider selling — The COO and a director disclosed multi‑lot sales in February (COO sale worth several million and director sales disclosed), which can create investor concern about near‑term insider conviction. Read More. Read More.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.